(VIANEWS) – Celsius Holdings (CELH), Eldorado Gold Corporation Ordinary Shares (EGO), GlaxoSmithKline (GSK) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Celsius Holdings (CELH)
42.5% sales growth and 23.23% return on equity
Celsius Holdings, Inc. develops, processes, markets, distributes, and sells functional energy drinks and liquid supplements in the United States, Australia, New Zealand, Canadian, European, Middle Eastern, Asia-Pacific, and internationally. The company offers CELSIUS, a fitness drink or supplement designed to accelerate metabolism and burn body fat; various flavors and carbonated and non-carbonated functional energy drinks under the CELSIUS Originals and Vibe name, as well as functional energy drink under the CELSIUS Essentials and CELSIUS On-the-Go Powder names; and CELSIUS ready-to drink products. It distributes its products through direct-to-store delivery, distributors, supermarkets, convenience stores, drug stores, nutritional stores, and mass merchants, as well as health clubs, gyms, the military, and e-commerce websites. The company was formerly known as Vector Ventures, Inc. and changed its name to Celsius Holdings, Inc. in January 2007. Celsius Holdings, Inc. was founded in 2004 and is headquartered in Boca Raton, Florida.
Earnings Per Share
As for profitability, Celsius Holdings has a trailing twelve months EPS of $0.77.
PE Ratio
Celsius Holdings has a trailing twelve months price to earnings ratio of 103.53. Meaning, the purchaser of the share is investing $103.53 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 23.23%.
Sales Growth
Celsius Holdings’s sales growth is 78.7% for the ongoing quarter and 42.5% for the next.
Previous days news about Celsius Holdings(CELH)
- According to Zacks on Monday, 13 May, "Investors interested in stocks from the Food – Miscellaneous sector have probably already heard of Ingredion (INGR Quick QuoteINGR – Free Report) and Celsius Holdings Inc. (CELH Quick QuoteCELH – Free Report) . ", "Ingredion and Celsius Holdings Inc. are sporting Zacks Ranks of #2 (Buy) and #3 (Hold), respectively, right now. "
- According to Zacks on Monday, 13 May, "Have you evaluated the performance of Celsius Holdings Inc.’s (CELH Quick QuoteCELH – Free Report) international operations during the quarter that concluded in March 2024? "
2. Eldorado Gold Corporation Ordinary Shares (EGO)
39.2% sales growth and 3.56% return on equity
Eldorado Gold Corporation and its subsidiaries engage in the exploration, discovery, acquisition, financing, development, production, sale, and reclamation of mineral products, primarily in Turkey, Canada, Greece, Brazil, and Romania. The company primarily produces gold, as well as silver, lead, zinc, and iron ore. It operates five mines: Kisladag and Efemcukuru located in western Turkey, Lamaque in Canada, and Olympias and Stratoni located in northern Greece. The company was formerly known as Eldorado Corporation Ltd. and changed its name to Eldorado Gold Corporation in April 1996. Eldorado Gold Corporation was founded in 1992 and is headquartered in Vancouver, Canada.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 3.56%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 13.2%, now sitting on 1.04B for the twelve trailing months.
Moving Average
Eldorado Gold Corporation Ordinary Shares’s value is below its 50-day moving average of $13.94 and under its 200-day moving average of $11.62.
Sales Growth
Eldorado Gold Corporation Ordinary Shares’s sales growth is 16.6% for the current quarter and 39.2% for the next.
Yearly Top and Bottom Value
Eldorado Gold Corporation Ordinary Shares’s stock is valued at $0.00 at 01:22 EST, under its 52-week low of $8.30.
3. GlaxoSmithKline (GSK)
14.3% sales growth and 38.78% return on equity
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.
Earnings Per Share
As for profitability, GlaxoSmithKline has a trailing twelve months EPS of $3.04.
PE Ratio
GlaxoSmithKline has a trailing twelve months price to earnings ratio of 13.38. Meaning, the purchaser of the share is investing $13.38 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 38.78%.
Yearly Top and Bottom Value
GlaxoSmithKline’s stock is valued at $40.66 at 01:22 EST, under its 52-week high of $45.10 and way above its 52-week low of $33.33.
Moving Average
GlaxoSmithKline’s worth is under its 50-day moving average of $42.06 and higher than its 200-day moving average of $38.35.
Dividend Yield
According to Morningstar, Inc., the next dividend payment is on May 16, 2024, the estimated forward annual dividend rate is 1.5 and the estimated forward annual dividend yield is 3.34%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 5.9%, now sitting on 30.74B for the twelve trailing months.
4. Terreno Realty Corporation (TRNO)
13.5% sales growth and 5.43% return on equity
Terreno Realty Corporation (“Terreno”, and together with its subsidiaries, “the Company”) acquires, owns and operates industrial real estate in six major coastal U.S. markets: Los Angeles, Northern New Jersey/New York City, San Francisco Bay Area, Seattle, Miami, and Washington, D.C. We invest in several types of industrial real estate, including warehouse/distribution (approximately 79.5% of our total annualized base rent as of December 31, 2021), flex (including light industrial and research and development, or R&D) (approximately 4.8%), transshipment (approximately 6.4%) and improved land (approximately 9.3%). We target functional properties in infill locations that may be shared by multiple tenants and that cater to customer demand within the various submarkets in which we operate. Infill locations are geographic locations surrounded by high concentrations of already developed land and existing buildings. As of December 31, 2021, we owned a total of 253 buildings aggregating approximately 15.1 million square feet, 36 improved land parcels consisting of approximately 127.1 acres and four properties under redevelopment that, upon completion, will consist of two properties aggregating approximately 0.2 million square feet and two improved land parcels aggregating approximately 12.1 acres. As of December 31, 2021, the buildings and improved land parcels were approximately 95.5% and 94.8% leased (including 0.4 million square feet of vacancy acquired during the fourth quarter of 2021), respectively, to 554 customers, the largest of which accounted for approximately 4.9% of our total annualized base rent.
Earnings Per Share
As for profitability, Terreno Realty Corporation has a trailing twelve months EPS of $1.92.
PE Ratio
Terreno Realty Corporation has a trailing twelve months price to earnings ratio of 28.6. Meaning, the purchaser of the share is investing $28.6 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.43%.
